GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Cyclically Adjusted Price-to-FCF

Albireo Pharma (FRA:BDQM) Cyclically Adjusted Price-to-FCF : (As of Jun. 09, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Albireo Pharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Albireo Pharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Cyclically Adjusted Price-to-FCF Chart

Albireo Pharma Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Albireo Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Albireo Pharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Albireo Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Albireo Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albireo Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Albireo Pharma's Cyclically Adjusted Price-to-FCF falls into.



Albireo Pharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Albireo Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, Albireo Pharma's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2022 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=-1.525/125.2265*125.2265
=-1.525

Current CPI (Sep. 2022) = 125.2265.

Albireo Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201212 -7.558 96.871 -9.770
201303 -10.408 98.209 -13.271
201306 -6.086 98.518 -7.736
201309 -4.088 98.790 -5.182
201312 -4.725 98.326 -6.018
201403 -6.791 99.695 -8.530
201406 -4.345 100.560 -5.411
201409 -3.612 100.428 -4.504
201412 -5.650 99.070 -7.142
201503 -4.037 99.621 -5.075
201506 -2.817 100.684 -3.504
201509 -1.533 100.392 -1.912
201512 -1.686 99.792 -2.116
201603 -1.579 100.470 -1.968
201606 -1.062 101.688 -1.308
201609 -0.975 101.861 -1.199
201612 0.000 101.863 0.000
201703 -1.281 102.862 -1.560
201706 -0.738 103.349 -0.894
201709 -0.495 104.136 -0.595
201712 -0.753 104.011 -0.907
201803 0.078 105.290 0.093
201806 -0.547 106.317 -0.644
201809 -0.737 106.507 -0.867
201812 -0.734 105.998 -0.867
201903 -0.997 107.251 -1.164
201906 -0.930 108.070 -1.078
201909 -1.003 108.329 -1.159
201912 -0.879 108.420 -1.015
202003 -1.524 108.902 -1.752
202006 -1.367 108.767 -1.574
202009 -1.404 109.815 -1.601
202012 -1.213 109.897 -1.382
202103 -1.524 111.754 -1.708
202106 -1.360 114.631 -1.486
202109 -1.189 115.734 -1.287
202112 -0.637 117.630 -0.678
202203 -1.670 121.301 -1.724
202206 -1.791 125.017 -1.794
202209 -1.525 125.227 -1.525

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Albireo Pharma  (FRA:BDQM) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Albireo Pharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Albireo Pharma (FRA:BDQM) Business Description

Industry
Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines